RU2013152648A - Аденовирус обезьян и гибридные аденовирусные векторы - Google Patents
Аденовирус обезьян и гибридные аденовирусные векторы Download PDFInfo
- Publication number
- RU2013152648A RU2013152648A RU2013152648/10A RU2013152648A RU2013152648A RU 2013152648 A RU2013152648 A RU 2013152648A RU 2013152648/10 A RU2013152648/10 A RU 2013152648/10A RU 2013152648 A RU2013152648 A RU 2013152648A RU 2013152648 A RU2013152648 A RU 2013152648A
- Authority
- RU
- Russia
- Prior art keywords
- sequence
- vector
- vector according
- locus
- seq
- Prior art date
Links
- 239000013598 vector Substances 0.000 title claims abstract 49
- 241000701161 unidentified adenovirus Species 0.000 title claims abstract 9
- 241000282693 Cercopithecidae Species 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 claims abstract 13
- 102000004169 proteins and genes Human genes 0.000 claims abstract 12
- 210000000234 capsid Anatomy 0.000 claims abstract 9
- 239000002773 nucleotide Substances 0.000 claims abstract 9
- 125000003729 nucleotide group Chemical group 0.000 claims abstract 9
- 108091026890 Coding region Proteins 0.000 claims abstract 8
- 108020004707 nucleic acids Proteins 0.000 claims abstract 8
- 102000039446 nucleic acids Human genes 0.000 claims abstract 8
- 150000007523 nucleic acids Chemical class 0.000 claims abstract 8
- 238000004806 packaging method and process Methods 0.000 claims abstract 5
- 108700026244 Open Reading Frames Proteins 0.000 claims abstract 4
- 101000936720 Streptococcus gordonii Accessory secretory protein Asp5 Proteins 0.000 claims abstract 4
- 239000000427 antigen Substances 0.000 claims abstract 4
- 108091007433 antigens Proteins 0.000 claims abstract 4
- 102000036639 antigens Human genes 0.000 claims abstract 4
- 229920001184 polypeptide Polymers 0.000 claims abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract 4
- 241001217856 Chimpanzee adenovirus Species 0.000 claims abstract 3
- 108010076504 Protein Sorting Signals Proteins 0.000 claims abstract 3
- 239000002671 adjuvant Substances 0.000 claims abstract 3
- 210000004102 animal cell Anatomy 0.000 claims abstract 3
- 230000003308 immunostimulating effect Effects 0.000 claims abstract 3
- 238000013518 transcription Methods 0.000 claims abstract 3
- 230000035897 transcription Effects 0.000 claims abstract 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 9
- 230000002163 immunogen Effects 0.000 claims 9
- 210000004027 cell Anatomy 0.000 claims 5
- 239000013603 viral vector Substances 0.000 claims 5
- 210000004436 artificial bacterial chromosome Anatomy 0.000 claims 4
- 108090000565 Capsid Proteins Proteins 0.000 claims 3
- 102100023321 Ceruloplasmin Human genes 0.000 claims 3
- 101710145505 Fiber protein Proteins 0.000 claims 3
- 241001465754 Metazoa Species 0.000 claims 3
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 230000028993 immune response Effects 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- QGMRQYFBGABWDR-UHFFFAOYSA-N sodium;5-ethyl-5-pentan-2-yl-1,3-diazinane-2,4,6-trione Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)NC1=O QGMRQYFBGABWDR-UHFFFAOYSA-N 0.000 claims 3
- 101710088335 Diacylglycerol acyltransferase/mycolyltransferase Ag85A Proteins 0.000 claims 2
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 230000006698 induction Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 102000018120 Recombinases Human genes 0.000 claims 1
- 108010091086 Recombinases Proteins 0.000 claims 1
- 108700019146 Transgenes Proteins 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 108091070501 miRNA Proteins 0.000 claims 1
- 239000002679 microRNA Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10044—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/20—Pseudochromosomes, minichrosomosomes
- C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Developmental Biology & Embryology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1108879.6 | 2011-05-25 | ||
| GBGB1108879.6A GB201108879D0 (en) | 2011-05-25 | 2011-05-25 | Vector |
| PCT/GB2012/000467 WO2012172277A1 (en) | 2011-05-25 | 2012-05-25 | Simian adenovirus and hybrid adenoviral vectors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2013152648A true RU2013152648A (ru) | 2015-06-27 |
Family
ID=44279666
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013152648/10A RU2013152648A (ru) | 2011-05-25 | 2012-05-25 | Аденовирус обезьян и гибридные аденовирусные векторы |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US9714435B2 (https=) |
| EP (2) | EP2714916B1 (https=) |
| JP (1) | JP6230527B2 (https=) |
| CN (1) | CN103930551B (https=) |
| AU (1) | AU2012270144B2 (https=) |
| BR (1) | BR112013030222A2 (https=) |
| CA (1) | CA2837274C (https=) |
| DK (1) | DK2714916T3 (https=) |
| ES (1) | ES2659183T3 (https=) |
| FR (1) | FR21C1026I1 (https=) |
| GB (1) | GB201108879D0 (https=) |
| NO (2) | NO2714916T3 (https=) |
| RU (1) | RU2013152648A (https=) |
| SG (2) | SG10201604179VA (https=) |
| WO (1) | WO2012172277A1 (https=) |
| ZA (1) | ZA201309016B (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2821989C1 (ru) * | 2021-01-21 | 2024-06-28 | Селлид Ко., Лтд. | Новый аденовирусный вектор, не включающий компетентный по репликации аденовирус, и его применение |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201108879D0 (en) * | 2011-05-25 | 2011-07-06 | Isis Innovation | Vector |
| SG11201407343XA (en) * | 2012-05-18 | 2014-12-30 | Univ Pennsylvania | Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof |
| SG11201507393TA (en) | 2013-03-14 | 2015-10-29 | Salk Inst For Biological Studi | Oncolytic adenovirus compositions |
| GB201413530D0 (en) | 2014-07-30 | 2014-09-10 | Isis Innovation | Treatment and prevention of malaria |
| KR102608590B1 (ko) | 2014-09-24 | 2023-12-01 | 솔크 인스티튜트 포 바이올로지칼 스터디즈 | 종양 살상 바이러스 및 이의 사용방법 |
| BR112017026523A2 (pt) * | 2015-06-12 | 2018-08-14 | Glaxosmithkline Biologicals Sa | vetor recombinante, adenovírus recombinante, composição, uso de um vetor recombinante, de um adenovírus recombinante ou de uma composição, método para induzir uma resposta imune em um indivíduo, e, polinucleotídeo isolado. |
| WO2017147269A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics |
| WO2017147265A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
| GB2549809C (en) | 2016-06-23 | 2022-11-30 | Univ Oxford Innovation Ltd | Vector |
| EP3532082A4 (en) | 2016-12-12 | 2020-08-26 | Salk Institute for Biological Studies | SYNTHETIC ADENOVIRUS TUMOR TARGETING AND THEIR USES |
| CN106916851A (zh) * | 2017-03-01 | 2017-07-04 | 广州恩宝生物医药科技有限公司 | 一种复制缺陷型人14型腺病毒载体及其制备方法和应用 |
| KR20230166145A (ko) | 2017-03-15 | 2023-12-06 | 옥스포드 바이오메디카(유케이) 리미티드 | 방법 |
| EP3634449A4 (en) | 2017-05-08 | 2021-03-17 | Gritstone Oncology, Inc. | ALPHAVIRUS NEOANTIGEN VECTORS |
| GB201708444D0 (en) | 2017-05-26 | 2017-07-12 | Univ Oxford Innovation Ltd | Compositions and methods for inducing an immune response |
| MX2020007077A (es) | 2018-01-04 | 2020-10-28 | Iconic Therapeutics Inc | Anticuerpos anti-factor tisular, conjugados anticuerpo-farmaco y metodos relacionados. |
| CN112292449A (zh) | 2018-04-09 | 2021-01-29 | 萨克生物研究学院 | 具有增强的复制特性的溶瘤腺病毒组合物 |
| GB201812647D0 (en) | 2018-08-03 | 2018-09-19 | Chancellor Masters And Scholars Of The Univ Of Oxford | Viral vectors and methods for the prevention or treatment of cancer |
| GB201814141D0 (en) * | 2018-08-30 | 2018-10-17 | Univ Oxford Innovation Ltd | Method and compositions for producing a virus |
| CN109797168A (zh) * | 2018-09-28 | 2019-05-24 | 广州佰芮慷生物科技有限公司 | 一种重组腺病毒的表达载体SAd23-L |
| US12377138B2 (en) | 2018-10-10 | 2025-08-05 | Oxford University Innovation Limited | Treatment and prevention of malaria |
| GB201818084D0 (en) | 2018-11-06 | 2018-12-19 | Univ Oxford Innovation Ltd | Compositions and methods |
| CN109602901B (zh) * | 2019-01-08 | 2022-05-27 | 成都迈科康生物科技有限公司 | 一种带状疱疹病毒疫苗及其制备方法和应用 |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| TWI810456B (zh) | 2019-05-22 | 2023-08-01 | 美商基利科學股份有限公司 | Tlr7調節化合物及hiv疫苗之組合 |
| AU2020279988A1 (en) | 2019-05-22 | 2021-12-23 | Aelix Therapeutics, S.L. | Dosage regimens for vaccines |
| MX2021014525A (es) | 2019-05-30 | 2022-03-17 | Gritstone Bio Inc | Adenovirus modificados. |
| DK4037708T3 (da) | 2019-09-30 | 2024-09-30 | Gilead Sciences Inc | HBV-vacciner og fremgangsmåder til at behandle HBV |
| AU2020384323A1 (en) | 2019-11-14 | 2022-06-02 | Aelix Therapeutics, S.L. | Dosage regimens for vaccines |
| CR20220220A (es) | 2019-11-18 | 2022-09-20 | Janssen Biotech Inc | Vacunas basadas en calr y jak2 mutantes y sus usos |
| JP2023512519A (ja) | 2020-01-31 | 2023-03-27 | ベス イスラエル ディーコネス メディカル センター インコーポレイテッド | コロナウイルス感染症を予防および処置するための組成物および方法－ｓａｒｓ－ｃｏｖ－２ワクチン |
| GB2594683A (en) | 2020-02-17 | 2021-11-10 | Vaxbio Ltd | Vaccine |
| GB202003611D0 (en) | 2020-03-12 | 2020-04-29 | Univ Oxford Innovation Ltd | Stabilised viral fusion proteins |
| JP2023517286A (ja) | 2020-03-13 | 2023-04-25 | オックスフォード ユニヴァーシティ イノヴェーション リミテッド | 免疫応答を誘導するための組成物及び方法 |
| RU2720614C9 (ru) * | 2020-04-23 | 2021-02-09 | федеральное государственное бюджетное учреждение «Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи» Министерства здравоохранения Российской Федерации | Иммунобиологическое средство и способ его использования для индукции специфического иммунитета против вируса тяжелого острого респираторного синдрома SARS-CoV-2 (варианты) |
| CA3183086A1 (en) | 2020-05-11 | 2021-11-18 | Janssen Pharmaceuticals, Inc. | Stabilized coronavirus spike protein fusion proteins |
| TWI867224B (zh) * | 2020-06-08 | 2024-12-21 | 中央研究院 | 重組抗體或片段，以及其用途 |
| US20230233661A1 (en) | 2020-06-29 | 2023-07-27 | Janssen Vaccines & Prevention B.V. | Vaccine combination against repiratory syncytial virus infection |
| US20230302119A1 (en) | 2020-07-06 | 2023-09-28 | Janssen Pharmaceuticals, Inc. | Stabilized Corona Virus Spike Protein Fusion Proteins |
| EP4175664A2 (en) | 2020-07-06 | 2023-05-10 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| GB2596820A (en) | 2020-07-07 | 2022-01-12 | Spicona Inc | Combination vaccine |
| CN116438308A (zh) | 2020-08-06 | 2023-07-14 | 磨石生物公司 | 多表位疫苗盒 |
| JP7369276B2 (ja) * | 2020-08-22 | 2023-10-25 | フェデラル ステート バジェタリー インスティテューション“ナショナル リサーチ センター フォー エピデミオロジー アンド マイクロバイオロジー ネームド アフター ザ オナラリー アカデミシャン エヌ．エフ．ガマレヤ”オブ ザ ミニストリー オブ ヘルス オブ ザ ロシアン フェデレーション | 重症急性呼吸器症候群ウイルスｓａｒｓ－ｃｏｖ－２に対する発現ベクター |
| JP2023541632A (ja) | 2020-09-15 | 2023-10-03 | インペリアル・カレッジ・イノベーションズ・リミテッド | 特発性肺線維症の処置 |
| GB202016604D0 (en) | 2020-10-20 | 2020-12-02 | Univ Of Oxford | Compositions and methods for inducing an immune response |
| GB202017673D0 (en) | 2020-11-09 | 2020-12-23 | Imperial College Innovations Ltd | Treatment of pulmonary arterial hypertensive |
| WO2022120176A2 (en) * | 2020-12-04 | 2022-06-09 | Gritstone Bio, Inc. | Compositions and methods of use thereof |
| GB202019455D0 (en) | 2020-12-10 | 2021-01-27 | Chancellor Masters And Scholars Of The Univ Of Oxford | Method for producing virus |
| GB202019454D0 (en) | 2020-12-10 | 2021-01-27 | Chancellor Masters And Scholars Of The Univ Of Oxford | Method for purifying virus |
| WO2022175479A1 (en) | 2021-02-19 | 2022-08-25 | Janssen Vaccines & Prevention B.V. | Vaccine combinations against respiratory syncytial virus strain a and b infections |
| WO2022175477A1 (en) | 2021-02-19 | 2022-08-25 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion rsv fb antigens |
| JP2024509769A (ja) | 2021-02-23 | 2024-03-05 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | 三量体安定化ｈｉｖエンベロープタンパク質変異 |
| KR20230165275A (ko) | 2021-04-01 | 2023-12-05 | 얀센 백신스 앤드 프리벤션 비.브이. | 안정화된 융합 전 piv3 f 단백질 |
| GB202105277D0 (en) | 2021-04-13 | 2021-05-26 | Imperial College Innovations Ltd | Signal peptides |
| WO2022234283A1 (en) | 2021-05-07 | 2022-11-10 | Astrazeneca Uk Limited | Compositions and methods for inducing an immune response |
| WO2023020939A1 (en) | 2021-08-17 | 2023-02-23 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
| WO2023026182A1 (en) | 2021-08-24 | 2023-03-02 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
| WO2023047348A1 (en) | 2021-09-24 | 2023-03-30 | Janssen Pharmaceuticals, Inc. | Stabilized corona virus spike protein fusion proteins |
| WO2023047349A1 (en) | 2021-09-24 | 2023-03-30 | Janssen Pharmaceuticals, Inc. | Stabilized coronavirus spike protein fusion proteins |
| EP4444347A1 (en) | 2021-12-07 | 2024-10-16 | Barinthus Biotherapeutics (UK) Limited | Vaccine boost methods and compositions |
| WO2023111725A1 (en) | 2021-12-14 | 2023-06-22 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
| EP4448802A1 (en) | 2021-12-16 | 2024-10-23 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion hmpv fusion proteins |
| WO2023156505A1 (en) | 2022-02-17 | 2023-08-24 | Janssen Vaccines & Prevention B.V. | Trimer stabilizing hiv envelope protein mutations r304v, n302m and t320l |
| WO2024061757A1 (en) | 2022-09-23 | 2024-03-28 | Janssen Vaccines & Prevention B.V. | Pre-fusion human piv1 f proteins |
| WO2024061759A1 (en) | 2022-09-23 | 2024-03-28 | Janssen Vaccines & Prevention B.V. | Stabilized coronavirus s proteins |
| WO2024074584A1 (en) | 2022-10-06 | 2024-04-11 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion piv3 f proteins |
| WO2024084441A1 (en) | 2022-10-19 | 2024-04-25 | Aelix Therapeutics, S.L. | Combination hiv vaccine |
| WO2024092028A2 (en) | 2022-10-25 | 2024-05-02 | Vaccitech North America, Inc. | Combination treatment regimes for treating cancer |
| GB202301244D0 (en) | 2023-01-27 | 2023-03-15 | Univ Oxford Innovation Ltd | Vaccine |
| GB202303328D0 (en) | 2023-03-07 | 2023-04-19 | Imperial College Innovations Ltd | Synthetic promoters |
| GB202305535D0 (en) | 2023-04-14 | 2023-05-31 | Imperial College Innovations Ltd | Oligonucleotide decoy |
| WO2024218165A1 (en) | 2023-04-17 | 2024-10-24 | Barinthus Biotherapeutics (Uk) Limited | Hpv viral vector vaccine |
| WO2025017540A1 (en) | 2023-07-20 | 2025-01-23 | Aelix Therapeutics, S.L. | Method of treatment of hiv infection with vaccine |
| CN117089577B (zh) * | 2023-08-21 | 2024-06-25 | 暨南大学 | 重组的猴腺病毒、病毒载体及构建方法 |
| WO2025052130A1 (en) | 2023-09-05 | 2025-03-13 | Oxford University Innovation Limited | Monoclonal antibody directed to reticulocyte-binding protein homologue 5 (pfrh5) |
| GB202400424D0 (en) | 2024-01-11 | 2024-02-28 | Cancer Research Tech Ltd | Treatment and prevention of lung cancer |
| WO2025168946A1 (en) | 2024-02-09 | 2025-08-14 | Oxford University Innovation Limited | Pfrh5 immunogen |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3650939A (en) | 1964-11-12 | 1972-03-21 | Ppg Industries Inc | Alkali chlorine cell |
| CA2271450A1 (en) | 1999-05-12 | 2000-11-12 | Stuart Energy Systems Inc. | Hydrogen fuel replenishment process and apparatus |
| US20040136963A1 (en) * | 2001-06-22 | 2004-07-15 | The Trustees Of The University Of Pennsylvania | Simian adenovirus vectors and methods of use |
| AU2002365366B2 (en) * | 2001-11-21 | 2007-05-10 | The Trustees Of The University Of Pennsylvania | Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use |
| US20070205342A1 (en) | 2002-01-23 | 2007-09-06 | Edward Gabriel | Slip drive for leveling devices |
| US7481858B2 (en) | 2005-02-25 | 2009-01-27 | Societe Bic | Hydrogen generating fuel cell cartridges |
| DE602005017743D1 (de) * | 2004-01-23 | 2009-12-31 | Angeletti P Ist Richerche Bio | Impfstoffträger für schimpansen-adenovirus |
| US7617018B2 (en) | 2004-10-18 | 2009-11-10 | Innovative Design Solutions | Platform attitude adjustment augmentation method and apparatus |
| US7178337B2 (en) | 2004-12-23 | 2007-02-20 | Tassilo Pflanz | Power plant system for utilizing the heat energy of geothermal reservoirs |
| CN100578676C (zh) * | 2005-01-12 | 2010-01-06 | 明基电通股份有限公司 | 可调式升降支撑装置 |
| WO2007104792A2 (en) * | 2006-03-16 | 2007-09-20 | Crucell Holland B.V. | Recombinant adenoviruses based on serotype 26 and 48, and use thereof |
| EP1998804B1 (en) * | 2006-03-27 | 2014-04-16 | Crucell Holland B.V. | Compositions comprising a recombinant adenovirus and an adjuvant |
| EP2333091B1 (en) * | 2007-05-29 | 2017-06-21 | Nature Technology Corporation | Vectors and methods for genetic immunization |
| CN101883858B (zh) * | 2007-11-28 | 2015-07-22 | 宾夕法尼亚大学托管会 | 猿猴亚家族E腺病毒SAdV-39、-25.2、-26、-30、-37和-38及其应用 |
| DK2406289T3 (en) * | 2009-03-10 | 2017-05-01 | Baylor Res Inst | ANTIGEN PRESENTING CELL TARGETED ANTIVIRUS VACCINES |
| GB201108879D0 (en) * | 2011-05-25 | 2011-07-06 | Isis Innovation | Vector |
-
2011
- 2011-05-25 GB GBGB1108879.6A patent/GB201108879D0/en not_active Ceased
-
2012
- 2012-05-25 DK DK12723726.1T patent/DK2714916T3/en active
- 2012-05-25 WO PCT/GB2012/000467 patent/WO2012172277A1/en not_active Ceased
- 2012-05-25 RU RU2013152648/10A patent/RU2013152648A/ru not_active Application Discontinuation
- 2012-05-25 BR BR112013030222A patent/BR112013030222A2/pt not_active IP Right Cessation
- 2012-05-25 NO NO12723726A patent/NO2714916T3/no unknown
- 2012-05-25 CA CA2837274A patent/CA2837274C/en active Active
- 2012-05-25 SG SG10201604179VA patent/SG10201604179VA/en unknown
- 2012-05-25 AU AU2012270144A patent/AU2012270144B2/en active Active
- 2012-05-25 EP EP12723726.1A patent/EP2714916B1/en active Active
- 2012-05-25 JP JP2014511948A patent/JP6230527B2/ja active Active
- 2012-05-25 EP EP17204780.5A patent/EP3321367B1/en active Active
- 2012-05-25 ES ES12723726.1T patent/ES2659183T3/es active Active
- 2012-05-25 SG SG2013087747A patent/SG195181A1/en unknown
- 2012-05-25 CN CN201280036659.1A patent/CN103930551B/zh active Active
- 2012-05-25 US US14/119,413 patent/US9714435B2/en active Active
-
2013
- 2013-12-02 ZA ZA2013/09016A patent/ZA201309016B/en unknown
-
2017
- 2017-06-20 US US15/628,277 patent/US10646587B2/en active Active
-
2020
- 2020-04-15 US US16/849,301 patent/US11857640B2/en active Active
-
2021
- 2021-06-28 FR FR21C1026C patent/FR21C1026I1/fr active Active
- 2021-07-07 NO NO2021028C patent/NO2021028I1/no unknown
-
2023
- 2023-11-16 US US18/511,357 patent/US20240181078A1/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2821989C1 (ru) * | 2021-01-21 | 2024-06-28 | Селлид Ко., Лтд. | Новый аденовирусный вектор, не включающий компетентный по репликации аденовирус, и его применение |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3321367A2 (en) | 2018-05-16 |
| EP2714916A1 (en) | 2014-04-09 |
| ZA201309016B (en) | 2014-08-27 |
| US10646587B2 (en) | 2020-05-12 |
| US9714435B2 (en) | 2017-07-25 |
| SG195181A1 (en) | 2013-12-30 |
| CN103930551B (zh) | 2017-05-24 |
| US20150044766A1 (en) | 2015-02-12 |
| ES2659183T3 (es) | 2018-03-14 |
| WO2012172277A4 (en) | 2013-04-04 |
| GB201108879D0 (en) | 2011-07-06 |
| US20200360533A1 (en) | 2020-11-19 |
| US11857640B2 (en) | 2024-01-02 |
| BR112013030222A2 (pt) | 2016-12-06 |
| US20180000966A1 (en) | 2018-01-04 |
| JP6230527B2 (ja) | 2017-11-15 |
| CA2837274A1 (en) | 2012-12-20 |
| US20240181078A1 (en) | 2024-06-06 |
| JP2014516536A (ja) | 2014-07-17 |
| FR21C1026I1 (fr) | 2021-08-06 |
| EP3321367A3 (en) | 2018-07-25 |
| DK2714916T3 (en) | 2018-02-19 |
| EP3321367B1 (en) | 2021-09-29 |
| CN103930551A (zh) | 2014-07-16 |
| AU2012270144B2 (en) | 2017-03-16 |
| NO2714916T3 (https=) | 2018-06-09 |
| EP2714916B1 (en) | 2018-01-10 |
| CA2837274C (en) | 2021-05-25 |
| WO2012172277A1 (en) | 2012-12-20 |
| SG10201604179VA (en) | 2016-07-28 |
| NO2021028I1 (no) | 2021-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013152648A (ru) | Аденовирус обезьян и гибридные аденовирусные векторы | |
| JP2014516536A5 (https=) | ||
| EP3529363B1 (en) | Cytomegalovirus vectors eliciting t cells restricted by major histocompatibility complex e molecules | |
| CN1067722C (zh) | 腺病毒载体 | |
| US10688164B2 (en) | CMV vectors comprising microRNA recognition elements | |
| ES2647662T3 (es) | Vacunas de ADN infeccioso frente al virus chikungunya | |
| JP2019524140A5 (https=) | ||
| CN102741405A (zh) | 提高基因表达的系统和保持有该系统的载体 | |
| JP2003511010A (ja) | ヒト細胞中での発現用に最適化された合成ヒトパピローマウイルス遺伝子 | |
| CN104212802B (zh) | 一种肿瘤细胞广谱高活性启动子及其用途 | |
| CN112979829A (zh) | 融合蛋白及其在制备靶向新冠病毒sars-cov-2的疫苗中的应用 | |
| JP2026063215A5 (https=) | ||
| JP2020533968A5 (https=) | ||
| Mitrus et al. | Tumour therapy with genes encoding apoptin and E4orf4 | |
| CN102086453B (zh) | 以粘蛋白1和生存素为靶点的肿瘤dna疫苗及病毒载体疫苗 | |
| CN105879060B (zh) | 以成纤维激活蛋白α为靶点的肿瘤DNA疫苗及病毒载体疫苗 | |
| CN116726198B (zh) | 一种抗肿瘤药物及其在脑胶质瘤治疗中的应用 | |
| CN1242065C (zh) | 猪繁殖与呼吸综合征重组腺病毒和疫苗 | |
| CN102660579B (zh) | HBx和人IL-12双基因重组载体及抗肝癌疫苗 | |
| CN101775375B (zh) | 制备含eb病毒潜伏膜蛋白1,2基因的重组腺相关病毒及其应用 | |
| JP2024501841A (ja) | アデノウイルス血清型３５ヘルパーベクター | |
| CN114341361B (zh) | 星状病毒复制子的方法和组合物 | |
| CN103948943A (zh) | 一种可复制型肾癌治疗性dna疫苗 | |
| CN104830905B (zh) | Iba1和LAG‑3双基因共表达重组腺病毒载体及其制备方法和应用 | |
| Moon et al. | Construction of an avian hepatitis E virus replicon expressing heterologous genes and evaluation of its potential as an RNA vaccine platform |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20150526 |